



FGF10 Signaling in Heart Development, Homeostasis, Disease and Repair

Fabien Hubert, Sandy Payan, Francesca Rochais

► To cite this version:

Fabien Hubert, Sandy Payan, Francesca Rochais. FGF10 Signaling in Heart Development, Homeostasis, Disease and Repair. *Frontiers in Genetics*, 2018, 9, 10.3389/fgene.2018.00599 . hal-01986227

HAL Id: hal-01986227

<https://amu.hal.science/hal-01986227>

Submitted on 6 Feb 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License

FGF10 signaling in heart development, homeostasis, disease and repair

Fabien Hubert, Sandy Payan and Francesca Rochais

Aix-Marseille Univ, INSERM, MMG, U 1251, Marseille, France

Address correspondence to:
Dr. Francesca Rochais
Aix Marseille Université
MMG U 1251
27 Boulevard Jean Moulin
13005 Marseille, France
francesca.rochais@univ-amu.fr

Abstract

Essential muscular organ that provides the whole body with oxygen and nutrients, the heart is the first organ to function during embryonic development. Cardiovascular diseases, including acquired and congenital heart defects, are the leading cause of mortality in industrialized countries. Fibroblast Growth Factors (FGFs) are involved in a variety of cellular responses including proliferation, differentiation and migration. Among the 22 human/mouse FGFs, the secreted FGF10 ligand through the binding of its specific receptors (FGFR1b and FGFR2b) and subsequent activation of downstream signaling is known to play essential role in cardiac development, homeostasis and disease. FGF10 is one of the major marker of the early cardiac progenitor cells and a crucial regulator of differentiated cardiomyocyte proliferation in the developing embryo. Increasing evidence support the hypothesis that a detailed understanding of developmental processes is essential to identify targets for cardiac repair and regeneration. Indeed the activation of resident cardiomyocyte proliferation together with the injection of cardiac progenitors represent the most promising therapeutical strategies for cardiac regenerative medicine. The recent findings showing that FGF10 promotes adult cardiomyocyte cell cycle reentry and directs stem cell differentiation and cell reprogramming toward the cardiogenic lineage provide new insights into therapeutical strategies for cardiac regeneration and repair.

Keywords

FGF10, FGFR1/2, heart development, cardiomyocyte, cardiac regeneration

1 Introduction

2
3 The heart is an essential muscular organ that pumps blood and provides the whole body with
4 oxygen and nutrients. During embryonic development, the heart is the first organ to form and
5 cardiac morphogenesis is a tightly regulated process. Cardiovascular diseases including
6 congenital and acquired heart diseases are the leading cause of mortality in industrialized
7 countries (Writing Group *et al.*, 2016).
8

9 By mediating a variety of cellular response, Fibroblast Growth Factors (FGFs) are known to
10 play an essential role in cardiac development, homeostasis and disease. The human/mouse FGF
11 family comprises 22 members including secreted and intracellular FGFs. Secreted FGFs bind
12 and activate cell surface tyrosine kinase receptors (FGF receptors; FGFRs) encoded by four
13 genes (FGFR1-4). The alternate splicing of FGFR genes results in the generation of seven
14 different receptors, each of them displaying distinct ligand-binding properties (Zhang *et al.*,
15 2006). In contrast to secreted FGFs, intracellular FGFs serve as cofactors for voltage gated
16 sodium channels and other molecules (Ornitz and Itoh, 2015). Interaction between secreted
17 FGFs and their specific receptors is tightly regulated by extracellular binding proteins including
18 heparan sulfates and the Klotho family proteins that serve as cofactors and confer unique ligand-
19 receptor binding properties. Activated tyrosine kinase FGF receptors (FGFRs) mediate diverse
20 intracellular signaling cascades including the RAS-MAPK, PI3K-AKT, PLC γ , and STAT
21 signaling pathways (Ornitz and Itoh, 2015). Phylogenetic analysis suggest that secreted FGFs
22 can be grouped into 5 subfamilies of paracrine FGFs and one subfamily of endocrine FGFs.
23 The current consensus suggests that FGF10 belongs to a subfamily that comprises FGF3, FGF7,
24 FGF10 and FGF22. Receptor-ligand specificities are well described. Indeed, FGF3, 7, 10, and
25 22 have been shown to activate preferentially the IIIb splice variant of FGFR2. In addition
26 FGF3 and FGF10 also activate the IIIb splice variant of FGFR1 (Zhang *et al.*, 2006).
27 Nevertheless, ablation studies together with overlapping expression patterns strongly suggest
28 potential functional redundancy between FGF family members in the developing and adult
29 heart. Finally, the existence of heterodimer formation between FGFs and FGFRs may further
30 increase receptor-ligand interaction possibilities (Sun *et al.*, 2002) and thus the diversity of FGF
31 signaling.
32

33 Here we will review a detailed understanding of FGF signaling in cardiovascular development,
34 homeostasis, disease and repair, focusing on the particular role of the FGF10/FGFR1/FGFR2
35 pathway.
36

37 Developmental role of the FGF10 signaling

38
39 Heart development is an extremely complex process that can be divided in two major growth
40 phases distinguished by a shift in the major site of proliferation from an extracardiac progenitor
41 cell population to fetal cardiomyocytes. The early embryonic phase relies on the extensive
42 proliferation of cardiac progenitor cells termed the Second Heart Field (SHF) and their
43 progressive addition to the developing heart tube. Precise spatiotemporal control of second
44 heart field progenitor cell proliferation-differentiation balance is required for normal heart tube
45 elongation. Cardiac neural crest (CNC) cells, a second extracardiac cell population, play a
46 critical role in early heart development (Hutson and Kirby, 2007). Concomitant with SHF cell
47 addition to the outflow tract (OFT) of the heart, CNC migrate from the dorsal neural tube into
48 the OFT. Interactions between CNC cells and SHF progenitors are critical determinants for the
49 correct addition of SHF cells to the heart tube. In contrast to early heart tube development, fetal
50 heart growth is achieved through the proliferation of differentiated cardiomyocytes which tight

control is essential for the correct morphogenesis of the heart. Indeed, perturbations in the regulation of fetal cardiomyocyte proliferation lead to congenital heart defects.

During the early embryonic phase of heart morphogenesis, proper communication between cardiac progenitor cells is a prerequisite for correct heart tube elongation, looping and arterial pole alignment. FGFs are among the critical signals required for proper early cardiac morphogenesis (Kelly, 2012). By ensuring communication within and between developing heart progenitors, FGF signaling leads to their tight regulation of proliferation and specification. Indeed, transgenic mouse models with conditional inactivation of *Fgfr1/2*, conditional overexpression of *Sprouty2* (*Spry2*, which encodes an FGF signaling antagonist) or conditional ablation of *Frs2* (encoding a MAPK/ PI3K signaling adaptor protein) within the second heart field progenitor cell population revealed that interrupting autocrine FGF signaling in SHF mesoderm, by compromising SHF progenitor cell proliferation and by indirectly reducing cardiac neural crest cell recruitment into the outflow tract cushions, causes outflow tract misalignment and subsequently impaired cardiac morphogenesis (Park *et al.*, 2008; Zhang *et al.*, 2008). While FGFR-dependent regulation of second heart field proliferation seems to depend on the PI3K/AKT pathway (Luo *et al.*, 2015), the Ras/Erk downstream signaling seems to be required in the regulation of myocardial specification (Hutson *et al.*, 2010; Rochais *et al.*, 2009). All these studies thus strongly reveal iterative roles for FGF signaling in OFT development.

Multiple FGF ligands have been described to be expressed in cardiac progenitors and surrounding tissues (**Figure 1A-C**). FGF10 was identified as a specific endogenous marker of the SHF (Kelly *et al.*, 2001). While *Fgf10* expression is restricted to SHF progenitors (Kelly *et al.*, 2001), *Fgf8* is also expressed in the adjacent pharyngeal ectoderm and endoderm (Ilagan *et al.*, 2006; Mesbah *et al.*, 2012). *Fgf15* expression has been detected in the pharyngeal endoderm (Vincentz *et al.*, 2005) and *Fgf3* is expressed in the pharyngeal endoderm and ectoderm (Urness *et al.*, 2011).

The Wnt/ β -catenin signaling pathway a key regulator of SHF development transcriptionally controls *Fgf10* expression within SHF progenitors (Cohen *et al.*, 2007). Crucial transcription factors of SHF cardiac progenitor cell deployment are also known to control *Fgf10* expression. ISL1 and NKX2-5 control the expression of *Fgf10* in the SHF, through competitive binding to common regulatory elements in an intronic cardiac enhancer, thus respectively activating expression in progenitor cells and repressing transcription in differentiated myocytes (Watanabe *et al.*, 2012). TBX1 also activates *Fgf10* through T-box binding sites in the same enhancer element (Watanabe *et al.*, 2012).

Fgf10-null embryos, which die at birth due to lung aplasia, display altered heart morphology. In addition to the absence of pulmonary arteries and veins, *Fgf10* knockout embryos display an abnormal positioning of the ventricular apex in the thoracic cavity (Marguerie *et al.*, 2006; Rochais *et al.*, 2014). Nevertheless, early SHF deployment and subsequent heart tube elongation are not affected by *Fgf10* deletion. In contrast, deletion of the main FGF10 receptor, *Fgfr2b*, leads to major congenital heart defects including ventricular septal defects, OFT alignment defects, and thin and poorly trabeculated ventricles (Marguerie *et al.*, 2006) strongly suggesting the existence of functional redundancy between FGF10 and other FGFR2b ligands during the early steps of heart development. FGF8 appears to be the major ligand regulating cardiac progenitor cell deployment. A series of conditional loss of function experiments has revealed that *Fgf8*, through a cell-autonomous mechanism, is required for SHF expansion and thus OFT elongation, septation and subsequent ventriculoarterial alignment (Ilagan *et al.*, 2006; Park *et al.*, 2008). Interestingly, the fact that heterozygous deletion of *Fgf10* in combination

with homozygous loss of mesodermal *Fgf8* expression results in more severely altered anterior heart development (Watanabe *et al.*, 2010) strongly supports mesodermal FGF8 and FGF10 functional redundancy. In addition, FGF3 and FGF10 have been also shown to play redundant and dosage sensitive requirement during heart tube elongation (Urness *et al.*, 2011). All these studies highlight that critical FGF dosage, including FGF10, is crucial for SHF proliferation and deployment and thus for normal cardiac morphogenesis.

During the second phase of heart development (after embryonic day E10.5), subsequent growth and remodeling of the myocardium occur without significant further addition of cardiac progenitor cells to the heart. Instead, regulated proliferation of cardiac myocytes drives growth of the atrial and ventricular chambers. Tight spatio-temporal regulation of fetal cardiomyocyte proliferation thus appears to be required for proper heart formation and impairment of cardiomyocyte proliferation during fetal stages also results in congenital heart defects (Ahuja *et al.*, 2007). FGF signals, through cell-autonomous or paracrine mechanisms, have been described as crucial regulators of fetal cardiomyocyte proliferation (**Figure 1D-E**) (Smith and Bader, 2007). FGF ligands originating from the endocardium and the epicardium, including FGF9, FGF16 and FGF20, have been shown to regulate cardiomyocyte proliferation (Hotta *et al.*, 2008; Lavine *et al.*, 2005; Lu *et al.*, 2008). Recent reports revealed the implication of FGF10 in the regulation of fetal cardiomyocyte proliferation. *Fgf10* mutant heart analysis demonstrates that FGF10 signaling, through a cell-type autonomous mechanism, specifically controls fetal right ventricular cardiomyocyte proliferation. In fact, at fetal stages, FGF10/FGFR2b signaling promotes cardiomyocyte proliferation through the phosphorylation of the FOXO3 transcription factor and subsequent downregulation of the cyclin dependent kinase inhibitor p27^{kip1} expression (Rochais *et al.*, 2014). In addition, myocardial FGF10 signaling, through the paracrine activation of FGFR1 and FGFR2 in the epicardium, has been suggested to promote epicardial-derived cell migration into the compact myocardial layer (Vega-Hernandez *et al.*, 2011). In this study, the impairment in cardiac fibroblast numbers observed in *Fgf10*-mutant hearts, results indirectly in reduced fetal cardiomyocyte proliferation.

Despite cardiomyocyte proliferation, FGF signals, through redundant function of FGFR1 and FGFR2, originating from the epicardium and the endocardium, play pivotal role in coronary vasculature development (**Figure 1D**). In fact, in embryonic mouse heart, myocardial FGFR1/2 signaling by triggering Hedgehog signaling activation, *Vegf* and *Angiopoietin-2* expression, indirectly participate to the coronary vascular plexus formation and thus coronary vessel deployment (Lavine *et al.*, 2006). Here the precise requirement of the FGF10 ligand has not been explored.

Several members of the FGF family are expressed in the vascular network (Beenken and Mohammadi, 2009; Presta *et al.*, 2005). While the most studied FGF member, FGF2, is a potent inducer of angiogenesis, other FGFs (FGF 1, 2, 5, 7, 8, 16 and 18), but not FGF10, are expressed in endothelial and vascular smooth muscle cells (Antoine *et al.*, 2005). Despite predominant FGFR1 and FGFR2 expression endothelial cells (Presta *et al.*, 2005), mouse specific deletion of *Fgfr1* and *Fgfr2* in both endothelial and hematopoietic cell lineages has no impact on normal vascular development (House *et al.*, 2016; Oladipupo *et al.*, 2014). In contrast, in zebrafish, global FGFR signaling inhibition using allosteric inhibitor or a dominant negative form of the receptor revealed the critical requirement for FGF signaling in the maintenance vascular function and integrity (De Smet *et al.*, 2014; Murakami *et al.*, 2008). This strongly suggests, in mammals, the existence of functional redundancy between FGFR1, FGFR2 and FGFR3 that also expressed in endothelial cells.

FGF10 signaling in cardiac homeostasis

Soon after birth, the ability of cardiomyocytes to proliferate is strongly reduced, and cardiac growth transitions from hyperplastic to hypertrophic (Pasumarthi and Field, 2002). For nearly a century, the adult heart has been considered to be a post-mitotic organ; however, recent studies have highlighted the importance of the homeostasis of the adult heart in physiological conditions. Indeed extensive studies on adult mammalian hearts including the human heart have led to a consensus that new cardiomyocytes are indeed generated throughout life (Bergmann *et al.*, 2009; Bergmann *et al.*, 2015; Soonpaa and Field, 1998). In the healthy adult murine and human heart, cardiomyocyte renewal is currently estimated at 0.5% to 2% per year (Eschenhagen *et al.*, 2017).

Diverse FGFs and downstream signals, including FGF1, FGF2, FGF10 and p38 MAP kinase have been shown to be involved in the regulation of adult cardiomyocyte renewal (**Figure 2**). *In vitro* studies initially described FGF2 as a potent positive regulator of cardiomyocyte proliferation (Pasumarthi and Field, 2002). *In vitro* and *in vivo* experiments indicate that p38 MAP kinase inhibition alone (Jopling *et al.*, 2012b) or in combination with FGF1 treatment (Engel *et al.*, 2006; Engel *et al.*, 2005), leads to partial cardiomyocyte dedifferentiation and cell-cycle progression. Furthermore, in the adult zebrafish, epicardial cells addition to the ventricle has been shown to support cardiac homeostasis in an FGF-dependent fashion (Wills *et al.*, 2008). Finally, in the adult mouse heart, FGF10 has been described to be a potent regulator of cardiomyocyte proliferation. Indeed, temporal *Fgf10* overexpression rapidly enhanced adult cardiomyocyte cell cycle re-entry leading to increased ventricular wall thickness. While FGF10 regulation of fetal cardiomyocyte proliferation seems to occur through the FGFR2b, FGF10 may activate predominantly the FGFR1b to promote adult cardiomyocyte proliferation (Rochais *et al.*, 2014).

Implication of FGF10 signaling in cardiovascular diseases and repair

Cardiovascular diseases are the leading cause of mortality in industrialized countries (Writing Group *et al.*, 2016). Characterized by any molecular, cellular and physiological change in the myocardium, coronary vessels or valves, cardiac diseases result in cardiomyocyte loss and impaired cardiac function that ultimately lead to congestive heart failure. Multiple FGFs including FGF10 signaling have been described to play pathophysiological roles in the cardiovascular system (Itoh *et al.*, 2016).

Diverse studies highlighted a role for the FGFR1/2 signaling in the neovascularization after injury (**Figure 2**). In the zebrafish injured heart, epicardial *Fgfr2* expression is upregulated and FGFR signaling blockade leads to a failure in coronary neovascularization, resulting in severely impaired cardiac regeneration (Lepilina *et al.*, 2006). In addition, neovascularization and vascular remodeling in response to injury is severely impaired in endothelial specific FGFR1/2 deficient mice (House *et al.*, 2016; Oladipupo *et al.*, 2014). Finally, endothelium-targeted overexpression of constitutively active FGFR2 post-myocardial infarction results in anti-apoptotic action with enhanced angiogenesis (Matsunaga *et al.*, 2009).

While zebrafish adult heart fully regenerates after injury (Poss *et al.*, 2002), damaged adult mammalian myocardium is replaced by fibrotic scar tissue. The MAPK pathway plays a crucial role in adult zebrafish heart regeneration (**Figure 2**). Indeed, the induction of p38-MAPK activity prevents cardiomyocyte proliferation and subsequent heart regeneration (Jopling *et al.*, 2012a). In the adult mouse heart, p38 inhibitor injection, after acute myocardial injury,

enhances cardiomyocyte and endothelial cell proliferation and preserves cardiac remodeling and function (Engel *et al.*, 2006) strongly revealing that downstream FGF signaling may be beneficial to improve the limited innate regenerative capacities of the adult mammalian heart. In contrast to the adult heart, neonatal mammalian heart, including mouse, pig and human, possesses extensive regenerative capacities (Haubner *et al.*, 2016; Porrello *et al.*, 2011; Zhu *et al.*, 2018). Nevertheless, the rapid and dramatic decrease in cardiomyocyte proliferation rate during the first week of postnatal life (Pasumarthi and Field, 2002) results in severely limited regenerative capacities in adult, strongly supporting the hypothesis that a detailed understanding of the regulation of fetal cardiomyocyte proliferation is essential to identify targets for cardiac regeneration. As described above, FGF10 has been identified as a crucial regulator of fetal cardiomyocyte proliferation (Rochais *et al.*, 2014). The fact that decreased myocardial *Fgf10* expression has been observed in mouse postnatal heart during the time window where cardiomyocytes exit from the cell cycle (Rochais *et al.*, 2014), coinciding with the loss of regenerative capacities, suggests that FGF10 signaling may play a role in cardiac regeneration. However *Fgf10* overexpression in the neonatal mouse heart does not promote beneficial effects on post-natal cardiac regeneration (Rubin *et al.*, 2013). Nevertheless, the ability for FGF10 to specifically induce adult cardiomyocyte cell-cycle reentry in physiological conditions suggests that FGF10 might be able to promote cardiomyocyte renewal in the adult injured heart (Rochais *et al.*, 2014).

Together with the stimulation of existing cardiomyocyte renewal, cell therapy using the injection or tissue-based implantation of cardiac progenitor cells and direct reprogramming represent relevant therapeutic options for cardiac regenerative medicine (Tzahor and Poss, 2017). Several studies revealed the requirement of FGF10 signaling during stem cell specification into the cardiogenic lineage (**Figure 2**). Indeed, FGF10 signaling has been shown to play an important role in promoting cardiomyocyte differentiation in both embryonic and induced pluripotent stem cells (Chan *et al.*, 2010). Furthermore, in addition to improve the quality of cardiac reprogramming in mouse fibroblasts, and in combination with FGF2 and the vascular endothelial growth factor (VEGF), FGF10, through the RAS-MAPK and PI3K/AKT pathways, is able to convert partially reprogrammed cells into functional cardiomyocyte-like cells (Yamakawa *et al.*, 2015).

Conclusions

All the studies described in this review highlighted the crucial role for the FGF10 ligand and the related FGFR1/2 signaling in heart development, homeostasis and disease. The recent findings revealing a crucial role for FGF10 in controlling both adult cardiomyocyte cell cycle reentry and stem cell differentiation and cell reprogramming toward the cardiogenic lineage provide potential therapeutic strategies for cardiovascular diseases.

References

- Ahuja, P., Sdek, P., MacLellan, W.R. (2007). Cardiac myocyte cell cycle control in development, disease, and regeneration. *Physiol Rev.* 87, 521-544.
- Antoine, M., *et al.* (2005). Expression pattern of fibroblast growth factors (FGFs), their receptors and antagonists in primary endothelial cells and vascular smooth muscle cells. *Growth Factors.* 23, 87-95.
- Beenken, A., Mohammadi, M. (2009). The FGF family: biology, pathophysiology and therapy. *Nat Rev Drug Discov.* 8, 235-253.
- Bergmann, O., *et al.* (2009). Evidence for cardiomyocyte renewal in humans. *Science.* 324, 98-102.
- Bergmann, O., *et al.* (2015). Dynamics of Cell Generation and Turnover in the Human Heart. *Cell.* 161, 1566-1575.
- Chan, S.S., *et al.* (2010). Fibroblast growth factor-10 promotes cardiomyocyte differentiation from embryonic and induced pluripotent stem cells. *PLoS One.* 5, e14414.
- Cohen, E.D., *et al.* (2007). Wnt/beta-catenin signaling promotes expansion of Isl-1-positive cardiac progenitor cells through regulation of FGF signaling. *J Clin Invest.* 117, 1794-1804.
- De Smet, F., *et al.* (2014). Fibroblast growth factor signaling affects vascular outgrowth and is required for the maintenance of blood vessel integrity. *Chem Biol.* 21, 1310-1317.
- Engel, F.B., Hsieh, P.C., Lee, R.T., Keating, M.T. (2006). FGF1/p38 MAP kinase inhibitor therapy induces cardiomyocyte mitosis, reduces scarring, and rescues function after myocardial infarction. *Proc Natl Acad Sci U S A.* 103, 15546-15551.
- Engel, F.B., *et al.* (2005). p38 MAP kinase inhibition enables proliferation of adult mammalian cardiomyocytes. *Genes Dev.* 19, 1175-1187.
- Eschenhagen, T., *et al.* (2017). Cardiomyocyte Regeneration: A Consensus Statement. *Circulation.* 136, 680-686.
- Haubner, B.J., *et al.* (2016). Functional Recovery of a Human Neonatal Heart After Severe Myocardial Infarction. *Circ Res.* 118, 216-221.
- Hotta, Y., *et al.* (2008). Fgf16 is required for cardiomyocyte proliferation in the mouse embryonic heart. *Dev Dyn.* 237, 2947-2954.
- House, S.L., *et al.* (2016). Endothelial fibroblast growth factor receptor signaling is required for vascular remodeling following cardiac ischemia-reperfusion injury. *Am J Physiol Heart Circ Physiol.* 310, H559-571.
- Hutson, M.R., Kirby, M.L. (2007). Model systems for the study of heart development and disease. Cardiac neural crest and conotruncal malformations. *Semin Cell Dev Biol.* 18, 101-110.
- Hutson, M.R., *et al.* (2010). Arterial pole progenitors interpret opposing FGF/BMP signals to proliferate or differentiate. *Development.* 137, 3001-3011.
- Ilagan, R., *et al.* (2006). Fgf8 is required for anterior heart field development. *Development.* 133, 2435-2445.
- Itoh, N., Ohta, H., Nakayama, Y., Konishi, M. (2016). Roles of FGF Signals in Heart Development, Health, and Disease. *Front Cell Dev Biol.* 4, 110.
- Jopling, C., Sune, G., Faucherre, A., Fabregat, C., Izpisua Belmonte, J.C. (2012a). Hypoxia induces myocardial regeneration in zebrafish. *Circulation.* 126, 3017-3027.
- Jopling, C., Sune, G., Morera, C., Izpisua Belmonte, J.C. (2012b). p38alpha MAPK regulates myocardial regeneration in zebrafish. *Cell Cycle.* 11, 1195-1201.
- Kelly, R.G. (2012). The second heart field. *Curr Top Dev Biol.* 100, 33-65.
- Kelly, R.G., Brown, N.A., Buckingham, M.E. (2001). The arterial pole of the mouse heart forms from Fgf10-expressing cells in pharyngeal mesoderm. *Dev Cell.* 1, 435-440.
- Lavine, K.J., *et al.* (2006). Fibroblast growth factor signals regulate a wave of Hedgehog activation that is essential for coronary vascular development. *Genes Dev.* 20, 1651-1666.
- Lavine, K.J., *et al.* (2005). Endocardial and epicardial derived FGF signals regulate myocardial proliferation and differentiation in vivo. *Dev Cell.* 8, 85-95.
- Lepilina, A., *et al.* (2006). A dynamic epicardial injury response supports progenitor cell activity during zebrafish heart regeneration. *Cell.* 127, 607-619.

Lu, S.Y., *et al.* (2008). FGF-16 is required for embryonic heart development. *Biochem Biophys Res Commun.* 373, 270-274.

Luo, W., *et al.* (2015). Akt1 signaling coordinates BMP signaling and beta-catenin activity to regulate second heart field progenitor development. *Development.* 142, 732-742.

Marguerie, A., *et al.* (2006). Congenital heart defects in Fgfr2-IIIb and Fgf10 mutant mice. *Cardiovasc Res.* 71, 50-60.

Matsunaga, S., *et al.* (2009). Endothelium-targeted overexpression of constitutively active FGF receptor induces cardioprotection in mice myocardial infarction. *J Mol Cell Cardiol.* 46, 663-673.

Mesbah, K., *et al.* (2012). Identification of a Tbx1/Tbx2/Tbx3 genetic pathway governing pharyngeal and arterial pole morphogenesis. *Hum Mol Genet.* 21, 1217-1229.

Murakami, M., *et al.* (2008). The FGF system has a key role in regulating vascular integrity. *J Clin Invest.* 118, 3355-3366.

Oladipupo, S.S., *et al.* (2014). Endothelial cell FGF signaling is required for injury response but not for vascular homeostasis. *Proc Natl Acad Sci U S A.* 111, 13379-13384.

Ornitz, D.M., Itoh, N. (2015). The Fibroblast Growth Factor signaling pathway. *Wiley Interdiscip Rev Dev Biol.* 4, 215-266.

Park, E.J., *et al.* (2008). An FGF autocrine loop initiated in second heart field mesoderm regulates morphogenesis at the arterial pole of the heart. *Development.* 135, 3599-3610.

Pasumarthi, K.B., Field, L.J. (2002). Cardiomyocyte cell cycle regulation. *Circ Res.* 90, 1044-1054.

Porrello, E.R., *et al.* (2011). Transient regenerative potential of the neonatal mouse heart. *Science.* 331, 1078-1080.

Poss, K.D., Wilson, L.G., Keating, M.T. (2002). Heart regeneration in zebrafish. *Science.* 298, 2188-2190.

Presta, M., *et al.* (2005). Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. *Cytokine Growth Factor Rev.* 16, 159-178.

Rochais, F., Mesbah, K., Kelly, R.G. (2009). Signaling pathways controlling second heart field development. *Circ Res.* 104, 933-942.

Rochais, F., *et al.* (2014). FGF10 promotes regional foetal cardiomyocyte proliferation and adult cardiomyocyte cell-cycle re-entry. *Cardiovasc Res.* 104, 432-442.

Rubin, N., Darehzereshki, A., Bellusci, S., Kaartinen, V., Ling Lien, C. (2013). FGF10 Signaling Enhances Epicardial Cell Expansion during Neonatal Mouse Heart Repair. *J Cardiovasc Dis Diagn.* 1.

Smith, T.K., Bader, D.M. (2007). Signals from both sides: Control of cardiac development by the endocardium and epicardium. *Semin Cell Dev Biol.* 18, 84-89.

Soonpaa, M.H., Field, L.J. (1998). Survey of studies examining mammalian cardiomyocyte DNA synthesis. *Circ Res.* 83, 15-26.

Sun, S., *et al.* (2002). Expression, purification, and kinetic characterization of full-length human fibroblast activation protein. *Protein Expr Purif.* 24, 274-281.

Tzahor, E., Poss, K.D. (2017). Cardiac regeneration strategies: Staying young at heart. *Science.* 356, 1035-1039.

Urness, L.D., Bleyl, S.B., Wright, T.J., Moon, A.M., Mansour, S.L. (2011). Redundant and dosage sensitive requirements for Fgf3 and Fgf10 in cardiovascular development. *Dev Biol.* 356, 383-397.

Vega-Hernandez, M., Kovacs, A., De Langhe, S., Ornitz, D.M. (2011). FGF10/FGFR2b signaling is essential for cardiac fibroblast development and growth of the myocardium. *Development.* 138, 3331-3340.

Vincentz, J.W., McWhirter, J.R., Murre, C., Baldini, A., Furuta, Y. (2005). Fgf15 is required for proper morphogenesis of the mouse cardiac outflow tract. *Genesis.* 41, 192-201.

Watanabe, Y., *et al.* (2010). Role of mesodermal FGF8 and FGF10 overlaps in the development of the arterial pole of the heart and pharyngeal arch arteries. *Circ Res.* 106, 495-503.

Watanabe, Y., *et al.* (2012). Fibroblast growth factor 10 gene regulation in the second heart field by Tbx1, Nkx2-5, and Islet1 reveals a genetic switch for down-regulation in the myocardium. *Proc Natl Acad Sci U S A.* 109, 18273-18280.

Wills, A.A., Holdway, J.E., Major, R.J., Poss, K.D. (2008). Regulated addition of new myocardial and epicardial cells fosters homeostatic cardiac growth and maintenance in adult zebrafish. *Development*. 135, 183-192.

Writing Group, M., *et al.* (2016). Executive Summary: Heart Disease and Stroke Statistics--2016 Update: A Report From the American Heart Association. *Circulation*. 133, 447-454.

Yamakawa, H., *et al.* (2015). Fibroblast Growth Factors and Vascular Endothelial Growth Factor Promote Cardiac Reprogramming under Defined Conditions. *Stem Cell Reports*. 5, 1128-1142.

Zhang, J., *et al.* (2008). *Frs2*alpha-deficiency in cardiac progenitors disrupts a subset of FGF signals required for outflow tract morphogenesis. *Development*. 135, 3611-3622.

Zhang, X., *et al.* (2006). Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. *J Biol Chem*. 281, 15694-15700.

Zhu, W., *et al.* (2018). Regenerative Potential of Neonatal Porcine Hearts. *Circulation*.

